Inflammatory cytokines and cardiovascular disease

Area of Science:

• Cardiovascular Medicine
• Immunology
• Biochemistry

Background:

• Atherosclerosis is increasingly recognized as a chronic inflammatory process.
• Key inflammatory mediators include interleukin-6 (IL-6), C-reactive protein (CRP), monocyte chemoattractant protein-1 (MCP-1), and interleukin-8 (IL-8).
• These cytokines are implicated in plaque inflammation, vulnerability, and recruitment of monocytes/macrophages.

Purpose of the Study:

• To explore the role of inflammatory cytokines in atherosclerosis and cardiovascular events.
• To investigate the impact of these cytokines on acute myocardial infarction, unstable angina, and restenosis after percutaneous coronary intervention.
• To examine the therapeutic potential of modulating these cytokines.

Main Methods:

• Review of existing literature on inflammatory cytokines in atherosclerosis.
• Analysis of plasma concentrations of cytokines in various cardiovascular conditions.
• Discussion of molecular mechanisms involving transcription factors (NF-κB, PPARs) and signaling proteins (Rho).

Main Results:

• Elevated IL-6, CRP, MCP-1, and IL-8 levels correlate with plaque inflammation and vulnerability.
• Circulating cytokine levels increase in acute myocardial infarction and unstable angina, but not stable angina.
• Cytokine levels rise post-percutaneous coronary intervention, linked to restenosis.
• Angiotensin II and atherogenic factors induce cytokines via transcription factors.
• Statins inhibit these proinflammatory factors, potentially via Rho.
• Interleukin-10 (IL-10) demonstrates anti-inflammatory effects.

Conclusions:

• Therapeutic modulation of inflammatory cytokines holds promise for preventing atherosclerosis and cardiovascular events.
• Targeting IL-6, IL-8, MCP-1, and related pathways offers potential treatment strategies.
• Interleukin-10 gene therapy may benefit complex cardiovascular disease cases.